New advances in treating thrombotic diseases: GPVI as a platelet drug target
- 1 September 2014
- journal article
- review article
- Published by Elsevier BV in Drug Discovery Today
- Vol. 19 (9), 1471-1475
- https://doi.org/10.1016/j.drudis.2014.06.005
Abstract
No abstract availableKeywords
This publication has 48 references indexed in Scilit:
- The GPVI – Fc Fusion Protein Revacept Reduces Thrombus Formation and Improves Vascular Dysfunction in Atherosclerosis without Any Impact on Bleeding TimesPLOS ONE, 2013
- An adenine insertion in exon 6 of human GP6 generates a truncated protein associated with a bleeding disorder in four Chilean familiesJournal of Thrombosis and Haemostasis, 2013
- Synergism between platelet collagen receptors defined using receptor-specific collagen-mimetic peptide substrata in flowing bloodBlood, 2010
- Platelets Amplify Inflammation in Arthritis via Collagen-Dependent Microparticle ProductionScience, 2010
- Molecular priming of Lyn by GPVI enables an immune receptor to adopt a hemostatic roleProceedings of the National Academy of Sciences of the United States of America, 2009
- Absence of collagen-induced platelet activation caused by compound heterozygous GPVI mutationsBlood, 2009
- Complementary roles of platelets and coagulation in thrombus formation on plaques acutely ruptured by targeted ultrasound treatment: a novel intravital modelJournal of Thrombosis and Haemostasis, 2009
- A novel antiplatelet antibody therapy that induces cAMP-dependent endocytosis of the GPVI/Fc receptor γ-chain complexJCI Insight, 2008
- Structural basis for platelet collagen responses by the immune-type receptor glycoprotein VIBlood, 2006
- Analysis of the Interaction of Platelet Collagen Receptor Glycoprotein VI (GPVI) with Collagen: A DIMERIC FORM OF GPVI, BUT NOT THE MONOMERIC FORM, SHOWS AFFINITY TO FIBROUS COLLAGENPublished by Elsevier BV ,2002